We engineered the BLISH, which included metastatic melanoma spheroids with a perfusable BV and LV pair, to evaluate the effect of administration of the BRAF and PI3K inhibitors on melanoma intravasation (Figure 5Ai). The gene discussed is BRAF; the disease is melanoma.